Immunic Inc. Stock
Price
Target price
€0.66
€0.66
-0.150%
-0.001
-0.150%
€8.84
24.10.25 / Tradegate
WKN: A2PHD4 / Symbol: IMUX / Name: Immunic / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Immunic Inc. Stock
Immunic Inc. shows a slight decrease today, losing -€0.001 (-0.150%) compared to yesterday.
The stock is one of the favorites of our community with 21 Buy predictions and 1 Sell predictions.
Based on the current price of 0.66 € the target price of 8 € shows a potential of 1112.12% for Immunic Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Immunic Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Immunic Inc. in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Immunic Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Immunic Inc. | -0.150% | -3.790% | -11.883% | -48.397% | -34.718% | -61.561% | -95.417% |
| NanoViricides Inc. | 0.830% | -5.469% | 1.681% | -10.370% | -19.333% | -27.761% | -62.188% |
| Actinium Pharmaceuticals Inc. | 22.080% | 13.651% | 3.394% | -7.969% | 24.414% | -80.083% | -84.926% |
| Ocuphire Pharma Inc. | 1.280% | 6.452% | 32.000% | 58.889% | 54.595% | -25.521% | - |
Comments
Immunic (NASDAQ:IMUX) was upgraded by analysts at LADENBURG THALM/SH SH to a "strong-buy" rating.
Show more
Ratings data for IMUX provided by MarketBeat
Immunic (NASDAQ:IMUX) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $3.00 price target on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
News
EQS-News: Immunic to Participate in Scientific and Investor Conferences in October
EQS-News: Immunic to Participate in Scientific and Investor Conferences in October
EQS-News: Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
EQS-News: Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
EQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
EQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis